Jim Robbins - Viveve Medical Principal Financial Officer
| VIVEDelisted Stock | USD 0.1 0.0005 0.53% |
Executive
Mr. Jim B. . Robbins serves as Principal Financial Officer of the company. He joined the Company as Vice President of Finance in July 2014 and was promoted to Vice President of Finance and Administration in May 2017. He was also appointed as the Company principal accounting officer in May 2018. He has over 20 years of accounting and finance experience in both industry and public accounting. Prior to joining the Company, from 2012 to 2014, Mr. Robbins provided accounting, finance and business consulting services for various biotech and other companies. From 2010 to 2012, he served as Vice President of Finance and Administration for Auxogyn, Inc., a privately held medical technology company focused on advancing womens reproductive health by translating scientific discoveries in early embryo development into clinical solutions that improve patient outcomes for in vitro fertilization procedures. He served as Director of Finance and Vice President of Finance from 2004 to 2010 for Micrus Endovascular, Inc., a company that develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Prior to Micrus Endovascular, Mr. Robbins served as Corporationrationrate Controller at Genitope Corporationrationration, a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. From 1995 to 2001, he served in management positions for technology companies including Extricity, Inc., InVision Technologies, Inc., and Truevision, Inc since 2018.
| Age | 59 |
| Tenure | 6 years |
| Phone | 720 696 8100 |
| Web | https://www.viveve.com |
Viveve Medical Management Efficiency
The company has return on total asset (ROA) of (0.6213) % which means that it has lost $0.6213 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1099) %, meaning that it created substantial loss on money invested by shareholders. Viveve Medical's management efficiency ratios could be used to measure how well Viveve Medical manages its routine affairs as well as how well it operates its assets and liabilities.Viveve Medical currently holds 5.12 M in liabilities with Debt to Equity (D/E) ratio of 1.12, which is about average as compared to similar companies. Viveve Medical has a current ratio of 1.29, suggesting that it may not have the ability to pay its financial obligations when due. Debt can assist Viveve Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Viveve Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viveve Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viveve to invest in growth at high rates of return. When we think about Viveve Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sean Wirtjes | Rapid Micro Biosystems | 55 | |
| Kimberly Bambach | Tivic Health Systems | 53 | |
| Michael Marcroft | SINTX Technologies | N/A | |
| Thomas Stankovich | ReShape Lifesciences | 63 | |
| John Kowalczyk | Nuwellis | N/A | |
| Sean CPA | Rapid Micro Biosystems | 55 | |
| Terri MBA | Cytosorbents Crp | N/A | |
| Christian MD | Cytosorbents Crp | N/A | |
| Robert Scott | Nuwellis | 43 | |
| Al Diaz | ReShape Lifesciences | N/A | |
| Lisa Wolf | Tivic Health Systems | 61 | |
| Kristine Williams | Rapid Micro Biosystems | N/A | |
| Irina Kulinets | Cytosorbents Crp | 69 | |
| Deina Walsh | Bone Biologics Corp | 60 | |
| Kevin Williamson | Tenon Medical | 39 | |
| FACC MBA | Nuwellis | N/A | |
| Amir Rippel | NanoVibronix | N/A | |
| David OBrien | SINTX Technologies | 59 | |
| Michael CFA | Rapid Micro Biosystems | N/A | |
| Stephen CPA | NanoVibronix | 68 | |
| Jodi Hoover | Cytosorbents Crp | N/A | |
Management Performance
| Return On Equity | -2.11 | ||||
| Return On Asset | -0.62 |
Viveve Medical Leadership Team
Elected by the shareholders, the Viveve Medical's board of directors comprises two types of representatives: Viveve Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viveve. The board's role is to monitor Viveve Medical's management team and ensure that shareholders' interests are well served. Viveve Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viveve Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jim Robbins, Principal Financial Officer | ||
| Martin PE, Dev Research | ||
| Suzon Lommel, VP Affairs | ||
| Lori McMillan, VP HR | ||
| Scott Durbin, CEO Director | ||
| Deborah MBA, Advisor Director | ||
| Jeannie Swindle, Sr Communications | ||
| Gary Kaiser, VP Marketing | ||
| Jeff Sinclair, VP Sales |
Viveve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Viveve Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.11 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (3.10) % | ||||
| Current Valuation | 4.26 M | ||||
| Shares Outstanding | 10.72 M | ||||
| Shares Owned By Institutions | 5.21 % | ||||
| Number Of Shares Shorted | 374.24 K | ||||
| Price To Earning | (2.59) X | ||||
| Price To Book | 3.62 X | ||||
| Price To Sales | 0.66 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Viveve Pink Sheet
If you are still planning to invest in Viveve Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viveve Medical's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |